Oncology
Refractory Solid Tumors
1
Pipeline Programs↗
29
Active Trials↗
35
Companies Involved↗
Refractory Solid Tumors is an early-stage landscape with 1 program across 35 companies. The most active players are XYone Therapeutics, Inc, Bristol-Myers Squibb, AstraZeneca.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
168
clinical trials
Completed107 · 64%
Recruiting16 · 10%
Terminated12 · 7%
Withdrawn10 · 6%
Unknown status9 · 5%
Active, not recruiting8 · 5%
Other6 · 4%
Clinical Trials
Trial Activity
168 trials
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Recruiting·—·Phase 1·NCT06500819·41 enrolled
AOH1996 for the Treatment of Refractory Solid Tumors
Recruiting·—·Phase 1·NCT05227326·92 enrolled
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
Recruiting·—·Phase 1·NCT03611595·18 enrolled
Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors
Recruiting·—·Phase 1·NCT06612645·9 enrolled
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)